Core Viewpoint - The ADC market in China is expected to exceed 100 billion RMB in the next five years, positioning it as the second-largest ADC market globally, driven by advancements in technology from Chinese companies like Innovent Biologics-B [1] Company Summary - Innovent Biologics-B (09606) saw its stock price increase by over 5%, currently trading at 308.4 HKD with a transaction volume of 104 million HKD [1] - The company's DB-1419 (B7-H3/PD-L1 dual antibody ADC) has shown excellent efficacy in clinical trials for solid tumors, indicating a significant technological breakthrough in the dual antibody ADC field [1] - Innovent plans to submit a market application for DB-1303 (HER2 ADC) for endometrial cancer in the U.S. and for breast cancer in China by 2025 [1] - The company’s DB-1311 (B7-H3 ADC) shows potential as a best-in-class treatment for prostate cancer, while DB-1310 (HER3 ADC) is expected to follow suit [1] - Innovent is leading global exploration in the combination of DB-1305 (TROP2 ADC) and dual antibodies, pushing the frontiers of next-generation ADCs [1] Industry Summary - According to a report by Frost & Sullivan, the global ADC market was valued at approximately 10.4 billion USD in 2023 and is projected to reach 115.1 billion USD by 2032 [1] - The ADC market in China is anticipated to grow significantly, reflecting the increasing investment and innovation in the biopharmaceutical sector [1]
港股异动 | 映恩生物-B(09606)盘中涨超5% 公司首款ADC有望于年内提交上市申请